Overview
Endomysial antibody is a highly specific IgA autoantibody used in the diagnosis of celiac disease and dermatitis herpetiformis. It targets the endomysium, which is the connective tissue surrounding smooth muscle fibers.
The antibody is produced following immune activation against gluten peptides modified by tissue transglutaminase. Because of its very high specificity for gluten-sensitive enteropathy, endomysial antibody testing is mainly used as a confirmatory test in suspected celiac disease.
Symptoms
Patients with positive endomysial antibodies commonly present with features of malabsorption such as chronic diarrhea, abdominal distension, weight loss, fatigue, and anemia. Extraintestinal manifestations may include osteoporosis, delayed growth, infertility, and neurological symptoms. In dermatitis herpetiformis, patients develop intensely pruritic vesicular skin lesions, often with minimal or absent gastrointestinal complaints.
Causes
Endomysial antibodies are produced due to an autoimmune response triggered by gluten ingestion in genetically predisposed individuals. Gluten exposure leads to activation of tissue transglutaminase, which modifies gluten peptides and induces antibody formation. The antibodies react with the reticulin component of smooth muscle endomysium and are strongly associated with villous atrophy of the small intestine. They are also seen in dermatitis herpetiformis, which shares the same immunopathogenesis.
Risk Factors
Risk factors for endomysial antibody positivity include a family history of celiac disease, the presence of autoimmune disorders such as type 1 diabetes or autoimmune thyroiditis, and genetic susceptibility. Selective IgA deficiency is an important risk factor that may cause false-negative IgA EMA results, requiring testing for IgG endomysial antibodies. Continued consumption of a gluten-containing diet increases the likelihood of antibody detection.
Prevention
Celiac disease cannot be prevented, but early detection using endomysial antibody testing helps prevent long-term complications. Strict adherence to a gluten-free diet leads to clinical improvement and the gradual disappearance of endomysial antibodies. Screening of high-risk individuals, appropriate confirmatory testing, and regular follow-up reduce disease-related morbidity and improve quality of life.
